MUC1 is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells

Breast Cancer Research and Treatment

Volumn 118, Issue 1, 2009, Pages 113-124

  Fessler, Shawn P ^a   Wotkowicz, Mark T ^a   Mahanta, Sanjeev K ^a   Bamdad, Cynthia ^a  

^a Minerva Biotechnologies   (United States)

Author keywords

Breast cancer; Chemotherapy; Drug resistance; Herceptin; MUC1; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MUCIN 1; PACLITAXEL; SHORT HAIRPIN RNA; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; HER2 PROTEIN, HUMAN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MUC1 PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR PROTEIN; WNT PROTEIN;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; UNITED STATES; BREAST TUMOR; CHEMISTRY; DIMERIZATION; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOLOGY; METABOLISM; MULTIDRUG RESISTANCE; PATHOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DIMERIZATION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MUCIN-1; NEOPLASM PROTEINS; PACLITAXEL; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 70349895167     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0412-3     Document Type: Article

References (41)

1. DJ Slamon W Godolphin LA Jones, et al. 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712 10.1126/science.2470152 10.1126/science.2470152 1:STN:280:DyaL1M3kt1Wntg%3D%3D 2470152
2. MX Sliwkowski 2003 Ready to partner Nat Struct Biol 10 158 159 10.1038/nsb0303-158 10.1038/nsb0303-158 1:CAS:528:DC%2BD3sXhsVaksb8%3D 12605220 (Pubitemid 36297983)
3. MM Moasser 2007 The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis Oncogene 26 6469 6487 10.1038/sj.onc.1210477 10.1038/sj.onc.1210477 1:CAS:528:DC%2BD2sXhtFagsbnN 17471238 (Pubitemid 47530601)
4. NJ Hellyer MS Kim JG Koland 2001 Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor J Biol Chem 276 42153 42161 10.1074/jbc.M102079200 10.1074/jbc.M102079200 1:CAS:528:DC%2BD3MXosVGnu7s%3D 11546794 (Pubitemid 37371123)
5. MA Cobleigh CL Vogel D Tripathy, et al. 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648 1:CAS:528:DyaK1MXmtlWrurk%3D 10561337
6. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 10.1056/NEJM200103153441101 10.1056/ NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D 11248153 (Pubitemid 32222155)
7. M Marty F Cognetti D Maraninchi, et al. 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265 4274 10.1200/JCO.2005.04.173 10.1200/JCO.2005.04.173 1:CAS:528: DC%2BD2MXms12gs70%3D 15911866 (Pubitemid 46207001)
8. EH Romond EA Perez J Bryant, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 10.1056/NEJMoa052122 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F 16236738 (Pubitemid 41464706)
9. HJ Burstein LN Harris R Gelman, et al. 2003 Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant Doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study J Clin Oncol 21 46 53 10.1200/JCO.2003.03.124 10.1200/JCO.2003.03.124 1:CAS:528:DC%2BD2cXpsVWru7g%3D 12506169
10. CL Vogel MA Cobleigh D Tripathy, et al. 2002 Efficacy and safety of trastuzumab as a single agent in first line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726 10.1200/JCO.20.3.719 10.1200/JCO.20.3.719 1:CAS:528:DC%2BD38XhsVGmt7o%3D 11821453 (Pubitemid 34111379)
11. F Montemurro S Redana F Nolè, et al. 2008 Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study BMC Cancer 8 209 217 10.1186/1471-2407-8-209 10.1186/1471-2407-8-209 18652678
12. CE Geyer J Forster D Lindquist, et al. 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743 10.1056/NEJMoa064320 10.1056/NEJMoa064320 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D 17192538 (Pubitemid 46021510)
13. S Paik R Hazan ER Fisher, et al. 1990 Pathologic findings from the national surgical adjuvant breast and bowel project: prognostic significance of erbB-2 protein overexpression in primary breast cancer J Clin Oncol 8 103 112 1:STN:280:DyaK3c7htFOktw%3D%3D 1967301
14. S Paik J Bryant E Tan-Chiu, et al. 2000 HER2 and choice of adjuvant chemotherapy for invasive breast cancer: national surgical adjuvant breast and bowel project protocol B-15 J Natl Cancer Inst 92 1991 1998 10.1093/jnci/92.24. 1991 10.1093/jnci/92.24.1991 1:CAS:528:DC%2BD3MXkvF2rsw%3D%3D 11121461
15. H Yamauchi A O'Neill R Gelman, et al. 1997 Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of HER-2/c-neu protein J Clin Oncol 15 2518 2525 1:CAS:528:DyaK2sXkslymsrs%3D 9215820
16. L Harris D Luftner W Jager, et al. 1999 c-erbB-2 in serum of patients with breast cancer Int J Biol Markers 14 8 15 1:STN:280:DyaK1M3psFehsg%3D%3D 10367244 (Pubitemid 29237570)
17. CT Chan MZ Metz SE Kane 2005 Differential sensitivities of trastuzumab (herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3 K) and epidermal growth factor receptor (EGFR) kinase inhibitors Breast Cancer Res Treat 91 187 201 10.1007/s10549-004-7715-1 10.1007/s10549-004-7715-1 1:CAS:528:DC%2BD2MXjvVWjsrs%3D 15868447 (Pubitemid 40684931)
18. P Nagy E Friedländer M Tanner, et al. 2005 Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line Cancer Res 65 473 482 1:CAS:528:DC%2BD2MXns1KqsA%3D%3D 15695389
19. R Nahta MC Hung FJ Esteva 2004 The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells Cancer Res 64 2343 2346 10.1158/0008-5472.CAN-03-3856 10.1158/0008-5472.CAN-03- 3856 1:CAS:528:DC%2BD2cXis1yjt7k%3D 15059883 (Pubitemid 38523885)
20. R Nahta LXH Yuan B Zhang, et al. 2005 Insulin-like growth factor-1 receptor/human epidermal growth factor receptor heterodimerization contributes to trastuzumab resistance of breast cancer cells Cancer Res 65 11118 11127 10.1158/0008-5472.CAN-04-3841 10.1158/0008-5472.CAN-04-3841 1:CAS:528: DC%2BD2MXht1KjsrrI 16322262 (Pubitemid 41713383)
21. CA Ritter M Perez-Torres C Rinehart, et al. 2007 Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network Clin Cancer Res 13 4909 4919 10.1158/1078-0432.CCR-07-0701 10.1158/1078-0432.CCR-07-0701 1:CAS:528:DC%2BD2sXptVGmtLg%3D 17699871 (Pubitemid 47294799)
22. L Yin L Huang D Kufe 2004 MUC1 oncoprotein activates the FOXO3 a transcription factor in a survival response to oxidative stress J Biol Chem 279 45721 45727 10.1074/jbc.M408027200 10.1074/jbc.M408027200 1:CAS:528: DC%2BD2cXovVCnsLk%3D 15322085 (Pubitemid 39491562)
23. D Raina S Kharbanda D Kufe 2004 The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts J Biol Chem 279 20607 20612 10.1074/jbc.M310538200 10.1074/jbc.M310538200 1:CAS:528:DC%2BD2cXjvV2gu7s%3D 14999001 (Pubitemid 38656454)
24. J Ren N Agata D Chen, et al. 2004 Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents Cancer Cell 5 163 175 10.1016/S1535-6108(04)00020-0 10.1016/S1535-6108(04)00020-0 1:CAS:528: DC%2BD2cXhvVOntb0%3D 14998492 (Pubitemid 38283802)
25. H Tsutsumida BJ Swanson PK Singh, et al. 2006 RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells Clin Cancer Res 12 2976 2987 10.1158/1078-0432.CCR-05- 1197 10.1158/1078-0432.CCR-05-1197 1:CAS:528:DC%2BD28Xks1CisbY%3D 16707592 (Pubitemid 43837341)
26. Y Li D Liu D Chen, et al. 2003 Human DF3/MUC1 carcinoma-associated protein functions as an oncogene Oncogene 22 6107 6110 10.1038/sj.onc.1206732 10.1038/sj.onc.1206732 1:CAS:528:DC%2BD3sXmvFansLg%3D 12955090 (Pubitemid 37175889)
27. S Mahanta SP Fessler J Park C Bamdad 2008 A minimal fragment of MUC1 mediates growth of cancer cells PLoS One 3 e2054 e2065 10.1371/journal.pone. 0002054 10.1371/journal.pone.0002054 18446242 (Pubitemid 352025042)
28. ST Hikita KS Kosik DO Clegg C Bamdad 2008 MUC1 mediates the growth of human pluripotent stem cells PLoS One 3 e3312 e3325 10.1371/journal.pone.0003312 10.1371/journal.pone.0003312 18833326
29. ML Scotti JF Langenheim S Tomblyn, et al. 2008 Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells Breast Cancer Res Treat 111 241 250 10.1007/s10549-007-9789-z 10.1007/s10549-007-9789-z 1:CAS:528: DC%2BD1cXptVCntLc%3D 17955362
30. P Kauraniemi S Hautaniemi R Autio, et al. 2004 Effects of herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines Oncogene 23 1010 1013 10.1038/sj.onc.1207200 10.1038/sj.onc.1207200 1:CAS:528:DC%2BD2cXntlemtg%3D%3D 14647448 (Pubitemid 38250948)
31. LL Luistro III JA Rosinski H Bian, et al. 2005 Herceptin-refractory ovarian carcinoma cells differentially express genes involved in angiogenesis, invasion and metastasis Proc Amer Assoc Cancer Res 46 5085 Abstract
32. J Lapointe C Li JP Higgins, et al. 2004 Gene expression profiling identifies clinically relevant subtypes of prostate cancer Proc Natl Acad Sci USA 101 811 816 10.1073/pnas.0304146101 10.1073/pnas.0304146101 1:CAS:528:DC%2BD2cXhsVWhu7o%3D 14711987 (Pubitemid 38121040)
33. S Lesperance I Popa M Bachvarova, et al. 2006 Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors Int J Oncol 29 5 24 1:CAS:528:DC%2BD28XntlWrs7Y%3D
34. Y Li W-H Yu J Ren, et al. 2003 Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein Mol Cancer Res 1 765 775 1:CAS:528:DC%2BD3sXms1Glu7w%3D 12939402
35. R Nahta FJ Esteva 2007 Trastuzumab; triumphs and tribulations Oncogene 26 3637 3643 10.1038/sj.onc.1210379 10.1038/sj.onc.1210379 1:CAS:528: DC%2BD2sXlslCqsbY%3D 17530017 (Pubitemid 46842713)
36. G Valabrega F Montemurro M Aglietta 2007 Trastuzumab: mechanism of action, resistance and future perspectives in Her2-overexpressing breast cancer Ann Oncol 18 977 984 10.1093/annonc/mdl475 10.1093/annonc/mdl475 1:STN:280:DC%2BD2szmvF2luw%3D%3D 17229773 (Pubitemid 47050487)
37. CL Vogel MA Cobleigh D Tripathy, et al. 2001 First-line herceptin monotherapy in metastatic breast cancer Oncol 61 37 42 10.1159/000055400 10.1159/000055400 1:CAS:528:DC%2BD3MXovFWjsLg%3D (Pubitemid 33033423)
38. SA Price-Schiavi S Jepson P Li, et al. 2002 Rat MUC4 (sialomucin complex) reduces binding of anti-ErbB2 antibody to tumor cell surfaces, a potential mechanism for herceptin resistance Int J Cancer 99 783 791 10.1002/ijc.10410 10.1002/ijc.10410 1:CAS:528:DC%2BD38XksVajs78%3D 12115478 (Pubitemid 34575694)
39. LN Harris F You SJ Schnitt, et al. 2007 Predictors of resistance to preoperative trastuzumab and vinorelbine for Her2-positive early breast cancer Clin Cancer Res 13 1198 1207 10.1158/1078-0432.CCR-06-1304 10.1158/1078-0432. CCR-06-1304 1:CAS:528:DC%2BD2sXhvF2hsbo%3D 17317830 (Pubitemid 46424061)
40. Y Lu H Zi D Zhao, et al. 2001 Insulin like growth factor-1 receptor signaling and resistance to trastuzumab (herceptin) J Natl Cancer Inst 93 1852 1857 10.1093/jnci/93.24.1852 10.1093/jnci/93.24.1852 1:CAS:528: DC%2BD38XltVWluw%3D%3D 11752009
41. JL Shattuck JK Miller KL Carraway III, et al. 2008 Met receptor contributes to trastuzumab resistance of Her2-overexpresssing breast cancer cells Cancer Res 68 1471 1477 10.1158/0008-5472.CAN-07-5962 10.1158/0008-5472. CAN-07-5962 1:CAS:528:DC%2BD1cXislagu70%3D 18316611 (Pubitemid 351346855)